Основная статистика
| CIK | 1402328 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Sunshine Biopharma, Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| August 12, 2025 |
Sunshine Biopharma Inc. 333 Las Olas Way, CU4 Suite 433 Fort Lauderdale, FL 33301 August 12, 2025 Sunshine Biopharma Inc. 333 Las Olas Way, CU4 Suite 433 Fort Lauderdale, FL 33301 August 12, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Sunshine Biopharma Inc. Post-Effective Amendment No. 2 to Registration Statement on Form S-1 Filed July 25, 2025 File No. 333-276817 Dear Sir or Madam: Pursuant to Rule 477 promu |
|
| August 12, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41282 SUNSH |
|
| August 12, 2025 |
Sunshine Biopharma Inc. 15,577,965 Shares of Common Stock Sunshine Biopharma Inc. S-1 Filed pursuant to Rule 424(b)(3) Under the Securities Act of 1933, as amended Registration No. 333-289230 PROSPECTUS Sunshine Biopharma Inc. 15,577,965 Shares of Common Stock Sunshine Biopharma Inc. is offering 15,577,965 shares of common stock. The shares are issuable upon exercise of outstanding Series B Warrants which were issued in our public offering that closed on |
|
| August 5, 2025 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-1 Sunshine Biopharma Inc. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Common Stock |
|
| August 5, 2025 |
As filed with the Securities and Exchange Commission on August 4, 2025 As filed with the Securities and Exchange Commission on August 4, 2025 Registration No. |
|
| July 25, 2025 |
As filed with the Securities and Exchange Commission on July 25, 2025 Table of Contents As filed with the Securities and Exchange Commission on July 25, 2025 Registration No. |
|
| May 19, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 SUNSHINE BIOPHARMA INC. (Exact name of registrant as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 19, 2025 |
Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year Exhibit 99.1 Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year FORT LAUDERDALE, FL / ACCESSWIRE / May 15, 2025 / Sunshine Biopharma Inc. (NASDAQ: “SBFM”) (the “Company”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its 202 |
|
| May 15, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41282 SUNS |
|
| April 3, 2025 |
Placement Agent Agreement, dated April 2, 2025 Exhibit 10.2 April 2, 2025 PERSONAL AND CONFIDENTIAL Dr. Steve Slilaty, Chief Executive Officer Sunshine Biopharma Inc. 333 Las Olas Way, CU4 Suite 433 Fort Lauderdale, FL 33301 Re: SBFM | Registered Direct Shelf Takedown | Placement Agent Agreement Dear Dr. Slilaty: The purpose of this placement agent agreement is to outline our agreement pursuant to which Aegis Capital Corp. (“Aegis”) will act a |
|
| April 3, 2025 |
Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 2, 2025, between Sunshine Biopharma Inc., a Colorado corporation (the “Company”), and each purchaser identified on the signature pages hereto (including their respective successors and assigns, each a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms an |
|
| April 3, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2025 SUNSHINE BIOPHARMA INC. (Exact name of registrant as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commission F |
|
| April 3, 2025 |
Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering Exhibit 99.2 Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering FORT LAUDERDALE, FL, APRIL 3, 2025 (ACCESS NEWSWIRE) - Sunshine Biopharma Inc. (NASDAQ: SBFM) (the “Company”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, today announced the closing of the previously ann |
|
| April 3, 2025 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-284142 PROSPECTUS SUPPLEMENT (To Prospectus dated January 15, 2025) 928,404 Shares of Common Stock Pre-Funded Warrants to Purchase 260,000 Shares of Common Stock 260,000 Shares of Common Stock Underlying the Pre-Funded Warrants Sunshine Biopharma Inc. is offering 928,404 shares of common stock, par value $0.001, pursuant to th |
|
| April 3, 2025 |
Exhibit 99.1 Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules FORT LAUDERDALE, FL, APRIL 2, 2025 (ACCESS NEWSWIRE) - Sunshine Biopharma Inc. (NASDAQ: SBFM) (the “Company”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, today announced that |
|
| April 3, 2025 |
Exhibit 10.3 REGISTERED PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK SUNSHINE BIOPHARMA INC. Warrant Shares: [●] Initial Exercise Date: April 2, 2025 Issuance Date: April 3, 2025 THIS PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditio |
|
| April 2, 2025 |
Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year Exhibit 99.1 Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year FORT LAUDERDALE, FL / ACCESSWIRE / April 1, 2025 / Sunshine Biopharma Inc. (NASDAQ: “SBFM”) (the “Company”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its 2024 annual repor |
|
| April 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2025 SUNSHINE BIOPHARMA INC. (Exact name of registrant as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commission F |
|
| April 1, 2025 |
Exhibit 19 SUNSHINE BIOPHARMA INC. Insider Trading Policy Purpose The purpose of this Insider Trading Policy (the "Policy") is to promote compliance with applicable insider trading laws and regulations of the United States and Canada, and to establish guidelines for the purchase, sale, and other dispositions of the Company's securities by directors, officers, employees, and consultants of Sunshine |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to Commission File Number 001-41282 SUNSHI |
|
| March 31, 2025 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Notification of Late Filing (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form N-SAR For Period Ended: December 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form N-SAR For the Transition Pe |
|
| January 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 SUNSHINE BIOPHARMA INC. (Exact name of registrant as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commissio |
|
| January 15, 2025 |
Employment Agreement between Sunshine Biopharma Inc. and Michel Roy Exhibit 10.1 EMPLOYMENT AGREEMENT THIS AGREEMENT is entered into on this 1st day of January, 2025: BETWEEN: SUNSHINE BIOPHARMA INC., a Colorado corporation, having its principal place of business located at 333 Las Olas Way, CU4 Suite 433, Fort Lauderdale, FL 33301 (Hereinafter referred to as the “COMPANY”); AND: Mr. Michel Roy residing at 18532 Thornburn Street, Pierrefonds, Quebec, H9K 1M9 (Here |
|
| January 15, 2025 |
SUNSHINE BIOPHARMA ANNOUNCES THE APPOINTMENT OF NEW CHIEF COMMERCIAL OFFICER Exhibit 99.1 SUNSHINE BIOPHARMA ANNOUNCES THE APPOINTMENT OF NEW CHIEF COMMERCIAL OFFICER FORT LAUDERDALE, FL / ACCESSWIRE / January 15, 2025 / Sunshine Biopharma Inc. (NASDAQ: “SBFM”) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals is pleased to announce the appointment of Mr. Michel Roy a |
|
| January 13, 2025 |
Sunshine Biopharma Inc. 333 Las Olas Way CU4 Suite 433 Fort Lauderdale, FL 33301 Sunshine Biopharma Inc. 333 Las Olas Way CU4 Suite 433 Fort Lauderdale, FL 33301 January 13, 2025 Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Re: Sunshine Biopharma Inc. Registration Statement on Form S-3 Filed January 6, 2025 File No. 333-284142 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, |
|
| January 6, 2025 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SUNSHINE BIOPHARMA INC. (Exact name of registrant as specified in its charter) Colorado 8731 20-5566275 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification No.) 333 Las Olas Way |
|
| January 6, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Sunshine Biopharma Inc. |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2024 SUNSHINE BIOPHARMA INC. (Exact name of registrant as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commissi |
|
| November 14, 2024 |
SBFM / Sunshine Biopharma, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-sbfm093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Sunshine Biopharma, Inc (Name of Issuer) Common Stock (Title of Class of Securities) 867781700 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| November 12, 2024 |
Sunshine Biopharma Inc. 12,934,062 Shares of Common Stock Sunshine Biopharma, Inc. 10-Q Filed pursuant to Rule 424(b)(4) Registration No. 333-276817 PROSPECTUS Sunshine Biopharma Inc. 12,934,062 Shares of Common Stock Sunshine Biopharma Inc. is offering 12,934,062 shares of common stock. The shares are issuable upon exercise of outstanding Series B Warrants which were issued in our public offering that closed on February 15, 2024, have a current exercise |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2024 SUNSHINE BIOPHARMA INC. (Exact name of registrant as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commissio |
|
| November 7, 2024 |
SUNSHINE BIOPHARMA REPORTS 2024 THIRD QUARTER RESULTS: YEAR-TO-DATE REVENUES UP 54% Exhibit 99.1 SUNSHINE BIOPHARMA REPORTS 2024 THIRD QUARTER RESULTS: YEAR-TO-DATE REVENUES UP 54% FORT LAUDERDALE, FL / ACCESSWIRE / November 6, 2024 / Sunshine Biopharma Inc. (NASDAQ: “SBFM”) (the “Company”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its 2024 third qu |
|
| November 6, 2024 |
Exhibit 3.10 Document must be filed electronically. Paper documents are not accepted. Fees & forms are subject to change. For more information or to print copies of filed documents, visit www.coloradosos.gov. ABOVE SPACE FOR OFFICE USE ONLY Statement of Correction Correcting the Entity Name filed pursuant to † 7 - 90 - 305 of the Colorado Revised Statutes (C.R.S.) 1. For the entity, its ID number |
|
| November 6, 2024 |
As filed with the Securities and Exchange Commission on November 6, 2024 Table of Contents As filed with the Securities and Exchange Commission on November 6, 2024 Registration No. |
|
| November 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41282 |
|
| October 23, 2024 |
Employment Agreement, dated October 21, 2024, between the Company and Camille Sebaaly Exhibit 10.2 EMPLOYMENT AGREEMENT THIS AGREEMENT dated this 21st day of October, 2024, nun pro tunc January 1, 2024, is: BETWEEN: SUNSHINE BIOPHARMA INC., a Colorado corporation having its principal place of business located at 333 Las Olas Way, CU4 Suite 433, Fort Lauderdale, FL 33301 (hereinafter referred to as the “COMPANY”); AND: Mr. Camille Sebaaly, residing at 3040 Levesque West, Suite 506, |
|
| October 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2024 SUNSHINE BIOPHARMA INC. (Exact name of registrant as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commissio |
|
| October 23, 2024 |
Employment Agreement, dated October 21, 2024, between the Company and Dr. Steve N. Slilaty Exhibit 10.1 AMENDED EMPLOYMENT AGREEMENT THIS AGREEMENT dated this 21st day of October, 2024, nun pro tunc January 1, 2024, is: BETWEEN: SUNSHINE BIOPHARMA INC., a Colorado corporation having its principal place of business located at 333 Las Olas Way, CU4 Suite 433, Fort Lauderdale, FL 33301 (hereinafter referred to as the “COMPANY”); AND: Dr. Steve N. Slilaty, residing at 579 Rue Lajeunesse, La |
|
| October 23, 2024 |
Employment Agreement, dated October 21, 2024, between the Company and Dr. Abderrazzak Merzouki Exhibit 10.3 EMPLOYMENT AGREEMENT THIS AGREEMENT dated this 21st day of October, 2024, nun pro tunc January 1, 2024, is: BETWEEN: SUNSHINE BIOPHARMA INC., a Colorado corporation having its principal place of business located at 333 Las Olas Way, CU4 Suite 433, Fort Lauderdale, FL 33301 (hereinafter referred to as the “COMPANY”); AND: Dr. Abderrazzak Merzouki, residing at 731 Place de l’Eeau Vive, |
|
| October 17, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under Rule 14a-12 Sunshine Biopharma Inc. |
|
| September 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2024 SUNSHINE BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commiss |
|
| August 20, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Num |
|
| August 19, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2024 SUNSHINE BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commissio |
|
| August 19, 2024 |
Exhibit 99.1 SUNSHINE BIOPHARMA REPORTS 2024 SECOND QUARTER RESULTS: SECOND QTR REVENUES UP 67%, YTD REVENUES UP 61% FORT LAUDERDALE, FL / ACCESSWIRE / August 19, 2024 / Sunshine Biopharma, Inc. (NASDAQ: “SBFM”) (the “Company”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has fil |
|
| August 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41282 SUNSH |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period E |
|
| August 12, 2024 |
Articles of Amendment to Articles of Incorporation Exhibit 3.1 ARTICLES OF AMENDMENT Relating to STOCK SPLIT TRANSACTION of SUNSHINE BIOPHARMA, INC Pursuant to CRS 7-106-105 of the Colorado Corporations and Associations Act I, Dr. Steve N. Slilaty, President and Chief Executive Officer of Sunshine Biopharma, Inc., (the “Company”), a corporation organized and existing under the Colorado Corporation and Association Act (the “Act”), in accordance wit |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 SUNSHINE BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commission |
|
| July 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☒ Definitive I |
|
| July 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2024 SUNSHINE BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commission |
|
| July 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C (Preliminary) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for use of the Commission Only (as permitted by Rule 14c-5(d)(2)) |
|
| July 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2024 SUNSHINE BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commission |
|
| June 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2024 SUNSHINE BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commission |
|
| June 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2024 SUNSHINE BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commission F |
|
| May 22, 2024 |
SUNSHINE BIOPHARMA REPORTS 2024 FIRST QUARTER RESULTS: REVENUES UP 54% Exhibit 99.1 SUNSHINE BIOPHARMA REPORTS 2024 FIRST QUARTER RESULTS: REVENUES UP 54% NEW YORK, NY / ACCESSWIRE / May 21, 2024 / Sunshine Biopharma, Inc. (NASDAQ: “SBFM”) (the “Company”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its 2024 first quarter report with the S |
|
| May 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2024 SUNSHINE BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commission F |
|
| May 20, 2024 |
(1`Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): [] Form 10-K [] Form 20-F [] Form 11-K [X] Form 10-Q [] Form N-SAR [] Form N-CSR For Period Ended: March 31, 2024 [] Transition Report on Form 10-K [] Transition Report on Form 20-F [] Transition Report on Form 11-K [] Transition Report on Form 10-Q [] Transition Report on F |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 SUNSHINE BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2024 SUNSHINE BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 6, 2024 |
Exhibit 16.1 May 6, 2024 United States Securities and Exchange Commission Office of the Chief Accountant 100 F Street, N.E. Washington, D.C. 20549 Re: Sunshine Biopharma, Inc. Ladies and Gentleman: We have read the statements under item 4.01 in the Form 8-K dated May 6, 2024, of Sunshine Biopharma, Inc. (the “Company”) to be filed with the Securities and Exchange Commission and we agree with such |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2024 SUNSHINE BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commission |
|
| April 23, 2024 |
Articles of Amendment to Articles of Incorporation Exhibit 3.1 ARTICLES OF AMENDMENT Relating to STOCK SPLIT TRANSACTION of SUNSHINE BIOPHARMA, INC Pursuant to CRS 7-106-105 of the Colorado Corporations and Associations Act I, Dr. Steve N. Slilaty, President and Chief Executive Officer of Sunshine Biopharma, Inc., (the “Company”), a corporation organized and existing under the Colorado Corporation and Association Act (the “Act”), in accordance wit |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2024 SUNSHINE BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commission |
|
| April 1, 2024 |
Exhibit 99.1 SUNSHINE BIOPHARMA REPORTS OPERATING RESULTS FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023 Sales Grew at an Average Rate of 14% Per Quarter During the Year NEW YORK, NY / ACCESSWIRE / April 1, 2024 / Sunshine Biopharma Inc. (NASDAQ: “SBFM”) (the “Company”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and an |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to Commission File Number 001-41282 SUNSHI |
|
| March 28, 2024 |
Exhibit 97.1 SUNSHINE BIOPHARMA, INC. CLAWBACK POLICY EFFECTIVE NOVEMBER 17, 2023 1. Purpose. The purpose of this Sunshine Biopharma, Inc. (the “Company”) Clawback Policy (this “Policy”) is to enable the Company to recover Erroneously Awarded Compensation from Covered Executive Officers in the event that the Company is required to prepare an Accounting Restatement. This Policy is designed to compl |
|
| March 28, 2024 |
SUNSHINE BIOPHARMA, INC. LIST OF SUBSIDIARIES EXHIBIT 21.1 SUNSHINE BIOPHARMA, INC. LIST OF SUBSIDIARIES Sunshine Biopharma Canada Inc. Nora Pharma Inc. |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Information Statement ¨ Confidential, for use of the Commission Only (as permitted by Rule 14c-5(d)(2)) x Definitive |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2024 SUNSHINE BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commission |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ¨ Preliminary Information Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14A-6(e)(2)) x Definitive Information Statement Sunshine Biopharma , Inc. (Name of R |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C (Preliminary) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Information Statement ¨ Confidential, for use of the Commission Only (as permitted by Rule 14c-5(d)(2) |
|
| March 1, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 SUNSHINE BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commiss |
|
| February 23, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Sunshine Biopharma, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 867781403 (CUSIP Number) February 13, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is f |
|
| February 21, 2024 |
Altium SC 13G Page 9 of 9 EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240. |
|
| February 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* SUNSHINE BIOPHARMA, INC. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 867781403 (CUSIP Number) February 13, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| February 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. ) Check the appropriate box: x Preliminary Information Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14A-6(e)(2)) ¨ Definitive Information Statement Sunshine Biopharma |
|
| February 16, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2024 SUNSHINE BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commiss |
|
| February 15, 2024 |
Exhibit 10.2 SERIES A WARRANT TO PURCHASE COMMON STOCK SUNSHINE BIOPHARMA, INC. Warrant Shares: [●] Initial Exercise Date: February 15, 2024 CUSIP: ISIN: Issue Date: February 15, 2024 THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions he |
|
| February 15, 2024 |
Underwriting Agreement, dated February 13, 2024 Exhibit 1.1 UNDERWRITING AGREEMENT February 13, 2024 Aegis Capital Corp. 1345 Avenue of the Americas, 27th Floor New York, NY 10105 Ladies and Gentlemen: Sunshine Biopharma, Inc., a Colorado corporation (the “Company”), agrees, subject to the terms and conditions in this agreement (this “Agreement”), to issue and sell to Aegis Capital Corp. (the “Underwriter”) an aggregate of 71,428,571 of the Com |
|
| February 15, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2024 SUNSHINE BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commiss |
|
| February 15, 2024 |
Sunshine Biopharma, Inc. Announces Closing of $10.0 Million Underwritten Public Offering Exhibit 99.2 Sunshine Biopharma, Inc. Announces Closing of $10.0 Million Underwritten Public Offering NEW YORK, NY / ACCESSWIRE / February 15, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the “Company”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, today announced the closing of a firm commitment unde |
|
| February 15, 2024 |
Sunshine Biopharma, Inc. Announces Pricing of $10.0 Million Underwritten Public Offering Exhibit 99.1 Sunshine Biopharma, Inc. Announces Pricing of $10.0 Million Underwritten Public Offering NEW YORK, FEBRUARY 13, 2024 - Sunshine Biopharma, Inc. (NASDAQ: SBFM) (the “Company”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, today announced the pricing of a firm commitment underwritten public o |
|
| February 15, 2024 |
Exhibit 10.3 SERIES B WARRANT TO PURCHASE COMMON STOCK SUNSHINE BIOPHARMA, INC. Warrant Shares: [●] Initial Exercise Date: February 15, 2024 CUSIP: ISIN: Issue Date: February 15, 2024 THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions he |
|
| February 14, 2024 |
Table of Contents Filed pursuant to Rule 424(b)(4) Registration No. 333-276817 PROSPECTUS 26,428,571 Common Units, Each Common Unit Consisting of One Share of Common Stock, one-tenth of a Series A Warrant to Purchase one Share of Common Stock and two-tenths of a Series B Warrant to Purchase one Share of Common Stock 45,000,000 Pre-Funded Units, Each Pre-Funded Unit Consisting of One Pre-Funded War |
|
| February 14, 2024 |
SBFM / Sunshine Biopharma, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-sbfm123123.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Sunshine Biopharma, Inc (Name of Issuer) Common Stock (Title of Class of Securities) 867781403 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 12, 2024 |
May 2023 Warrant Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) dated this 11th day of February, 2024, by and between Armistice Capital Master Fund Ltd. (the “Seller”) and Sunshine Biopharma, Inc. (the “Company”). W I T N E S S E T H: WHEREAS, the Seller is the holder of warrants (the “May 2023 Warrants”) to purchase 11,904,762 shares of common stock of the Company |
|
| February 12, 2024 |
Form of April 2022 Warrant Purchase Agreement Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) dated this 11th day of February, 2024, by and between (the “Seller”) and Sunshine Biopharma, Inc. (the “Company”). W I T N E S S E T H: WHEREAS, the Seller is the holder of warrants (the “April 2022 Warrants”) to purchase shares of common stock of the Company, dated April 28, 2022; WHEREAS, the Company |
|
| February 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2024 SUNSHINE BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commiss |
|
| February 9, 2024 |
Form of Series A Warrant for this Offering Exhibit 10.21 SERIES A WARRANT TO PURCHASE COMMON STOCK SUNSHINE BIOPHARMA, INC. Warrant Shares: [●] Initial Exercise Date: [●], 2024 CUSIP: ISIN: Issue Date: [●], 2024 THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set f |
|
| February 9, 2024 |
As filed with the Securities and Exchange Commission on February 9, 2024 Table of Contents As filed with the Securities and Exchange Commission on February 9, 2024 Registration No. |
|
| February 9, 2024 |
Form of Warrant Agency Agreement for this offering Exhibit 10.19 WARRANT AGENT AGREEMENT This WARRANT AGENT AGREEMENT (this “Warrant Agreement”) dated as of February , 2024 (the “Issuance Date”) is between Sunshine Biopharma, Inc., a Colorado corporation (the “Company”), and Equiniti Trust Company (the “Warrant Agent”). WHEREAS, pursuant to the terms of that certain Underwriting Agreement (“Underwriting Agreement”), dated February , 2024, by and a |
|
| February 9, 2024 |
Form of Series B Warrant for this Offering Exhibit 10.22 SERIES B WARRANT TO PURCHASE COMMON STOCK SUNSHINE BIOPHARMA, INC. Warrant Shares: [●] Initial Exercise Date: [●], 2024 CUSIP: ISIN: Issue Date: [●], 2024 THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set f |
|
| February 9, 2024 |
February 9, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| February 9, 2024 |
Form of Underwriting Agreement Exhibit 1.1 UNDERWRITING AGREEMENT [●], 2024 Aegis Capital Corp. 1345 Avenue of the Americas, 27th Floor New York, NY 10105 Ladies and Gentlemen: Sunshine Biopharma, Inc., a Colorado corporation (the “Company”), agrees, subject to the terms and conditions in this agreement (this “Agreement”), to issue and sell to Aegis Capital Corp. (the “Underwriter”) an aggregate of [●] of the Company’s units (e |
|
| February 9, 2024 |
Exhibit 10.20 PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK SUNSHINE BIOPHARMA, INC. Warrant Shares: [●] Initial Exercise Date: [●], 2024 Issue Date: [●], 2024 THIS PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set f |
|
| February 9, 2024 |
Sunshine Biopharma, Inc. 1177 Avenue of the Americas, 5th Floor New York , NY 10036 Sunshine Biopharma, Inc. 1177 Avenue of the Americas, 5th Floor New York , NY 10036 February 9, 2024 Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Re: Sunshine Biopharma, Inc. Registration Statement on Form S-1 File No. 333-276817 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Sunshi |
|
| February 1, 2024 |
As filed with the Securities and Exchange Commission on February 1, 2024 Table of Contents As filed with the Securities and Exchange Commission on February 1, 2024 Registration No. |
|
| February 1, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 Sunshine Biopharma, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Pric |
|
| January 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2024 SUNSHINE BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commissi |
|
| January 8, 2024 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Title of Securities to be Registered Amount to be Registered (1) Proposed Maximum Offering Price Per Share (2) Proposed Maximum Aggregate Offering Price (2) Amount of Registration Fee Common Stock, par value $0. |
|
| January 8, 2024 |
As filed with the Securities and Exchange Commission on January 8, 2024 As filed with the Securities and Exchange Commission on January 8, 2024 Registration No. |
|
| January 8, 2024 |
Exhibit 4.1 Sunshine Biopharma, Inc. 2023 Equity Incentive Plan 1. Purpose; Eligibility. 1.1 General Purpose. The name of this plan is the Sunshine Biopharma, Inc. 2023 Equity Incentive Plan (the "Plan"). The purposes of the Plan are to (a) enable Sunshine Biopharma, Inc., a Colorado corporation (the "Company"), to attract and retain the types of Employees, Consultants and Directors who will contr |
|
| December 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2023 SUNSHINE BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commissi |
|
| November 13, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41282 |
|
| November 13, 2023 |
Exhibit 99.1 November 13, 2023 SUNSHINE BIOPHARMA REPORTS 2023 THIRD QUARTER RESULTS: REVENUES UP SIGNIFICANTLY OVER LAST YEAR DUE TO A KEY ACQUISITION Montreal, Canada – (ACCESSWIRE) – Sunshine Biopharma Inc. (NASDAQ: “SBFM”) (the “Company”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 SUNSHINE BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commiss |
|
| November 2, 2023 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 SUNSHINE BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commissi |
|
| October 20, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2023 SUNSHINE BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commissi |
|
| October 20, 2023 |
Amendment No. 1 to Warrant Agent Agreement, dated October 18, 2023 Exhibit 10.1 AMENDMENT NO. 1 TO WARRANT AGENT AGREEMENT This Amendment No. 1 to Warrant Agent Agreement (this “Amendment”) dated this 18th day of October, 2023, by and among Sunshine Biopharma, Inc., a Colorado corporation (the “Company”) and Equiniti Trust Company (the “Warrant Agent”). WHEREAS, the Company and the Warrant Agent are parties to the warrant agent agreement, dated February 17, 2022 |
|
| October 19, 2023 |
SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| October 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under Rule 14a-12 Sunshine Biopharma, Inc. |
|
| October 13, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2023 SUNSHINE BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commissi |
|
| September 22, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2023 SUNSHINE BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commis |
|
| September 22, 2023 |
Exhibit 99.1 For Immediate Release September 21, 2023 SUNSHINE BIOPHARMA RECEIVES 180-DAY EXTENSION TO ACHIEVE NASDAQ MINIMUM BID COMPLIANCE No Immediate Effect on Nasdaq Listing or Trading of the Company's Common Stock Montreal, Canada – (ACCESSWIRE) – Sunshine Biopharma Inc. (NASDAQ: “SBFM”) (the “Company”), a pharmaceutical company offering and researching life-saving medicines in a variety of |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under Rule 14a-12 Sunshine Biopharma, Inc. |
|
| August 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under Rule 14a-12 Sunshine Biopharma, Inc. |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2023 SUNSHINE BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commissio |
|
| August 11, 2023 |
SUNSHINE BIOPHARMA REPORTS 2023 SECOND QUARTER RESULTS: REVENUES UP 3,600% Exhibit 99.1 For Immediate Release August 11, 2023 SUNSHINE BIOPHARMA REPORTS 2023 SECOND QUARTER RESULTS: REVENUES UP 3,600% Montreal, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma Inc. (NASDAQ: “SBFM”) (the “Company”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its |
|
| August 10, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41282 SUNSH |
|
| August 8, 2023 |
Sunshine Biopharma, Inc. 6500 Trans-Canada Highway, 4th Floor Pointe-Claire, Quebec, Canada H9R 0A5 Sunshine Biopharma, Inc. 6500 Trans-Canada Highway, 4th Floor Pointe-Claire, Quebec, Canada H9R 0A5 August 8, 2023 Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attn: Gary Newberry and Kevin Kuhar Re: Sunshine Biopharma, Inc. Form 10-K for the Fiscal Year Ended December 31, 2022 Filed April 4, 2023 File No. 001-41282 Dear Mr. Newberry an |
|
| June 5, 2023 |
17,857,143 Shares of Common Stock Table of Contents Filed pursuant to Rule 424(b)(3) Under the Securities Act of 1933, as amended Registration No. |
|
| June 1, 2023 |
Sunshine Biopharma, Inc. 6500 Trans-Canada Highway 4th Floor Pointe-Claire, Quebec, Canada H9R 0A5 Sunshine Biopharma, Inc. 6500 Trans-Canada Highway 4th Floor Pointe-Claire, Quebec, Canada H9R 0A5 June 1, 2023 Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Re: Sunshine Biopharma, Inc. Registration Statement on Form S-3 Filed May 25, 2023 File No. 333-272197 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities A |
|
| May 25, 2023 |
As filed with the Securities and Exchange Commission on May 25, 2023 Table of Contents As filed with the Securities and Exchange Commission on May 25, 2023 Registration No. |
|
| May 25, 2023 |
Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Sunshine Biopharma, Inc. |
|
| May 16, 2023 |
Placement Agent Agreement dated May 12, 2023 Exhibit 10.1 AEGIS CAPITAL CORP. May 12, 2023 PERSONAL AND CONFIDENTIAL Dr. Steve Slilaty, Chief Executive Officer Sunshine Biopharma, Inc. 6500 Trans-Canada Highway, 4th Floor Pointe-Claire, Québec, Canada H9R0A5 Re: SBFM Private Placement Dear Dr. Slilaty: The purpose of this placement agent agreement is to outline our agreement pursuant to which Aegis Capital Corp. (“Aegis”) will act as the pla |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2023 SUNSHINE BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commission F |
|
| May 16, 2023 |
Form of Registration Rights Agreement Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of May 12, 2023, between Sunshine Biopharma, Inc., a Colorado corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Purchase |
|
| May 16, 2023 |
Form of Securities Purchase Agreement Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 12, 2023, between Sunshine Biopharma, Inc., a Colorado corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions |
|
| May 16, 2023 |
Exhibit 10.5 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| May 16, 2023 |
Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| May 16, 2023 |
Sunshine Biopharma Announces Closing of $5.0 Million Private Placement Priced At-the-Market Exhibit 99.2 Sunshine Biopharma Announces Closing of $5.0 Million Private Placement Priced At-the-Market MONTREAL, May 16, 2023 (GLOBE NEWSWIRE) - Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, today closed its previously announced private placement pursuant to a |
|
| May 16, 2023 |
Sunshine Biopharma Announces Pricing of $5.0 Million Private Placement Priced At-the-Market Exhibit 99.1 Sunshine Biopharma Announces Pricing of $5.0 Million Private Placement Priced At-the-Market MONTREAL, May 12, 2023 (GLOBE NEWSWIRE) - Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, today announced that it entered into a securities purchase agreement w |
|
| May 11, 2023 |
SUNSHINE BIOPHARMA REPORTS 2023 FIRST QUARTER RESULTS: REVENUES UP 2,100% Exhibit 99.1 For Immediate Release May 11, 2023 SUNSHINE BIOPHARMA REPORTS 2023 FIRST QUARTER RESULTS: REVENUES UP 2,100% Montreal, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its 2023 first quarter r |
|
| May 11, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 SUNSHINE BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commission F |
|
| May 10, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41282 SUNS |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under Rule 14a-12 Sunshine Biopharma, Inc. |
|
| April 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2023 SUNSHINE BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commission |
|
| April 19, 2023 |
Exhibit 3.1 INDEX TO THE BYLAWS OF SUNSHINE BIOPHARMA, INC. ARTICLE I - OFFICES 1 Section 1. Offices 1 Section 2. Registered Office 1 ARTICLE II - SHAREHOLDERS 1 Section 1. Annual Meeting 1 Section 2. Special Meetings 1 Section 3. Place of Meetings 1 Section 4. Notice of Meeting 2 Section 5. Fixing of Record Date 2 Section 6. Voting Lists 3 Section 7. Recognition Procedure for Beneficial Owners 3 |
|
| April 4, 2023 |
SHINSHINE BIOPHARMA, INC. LIST OF SUBSIDIARIES Exhibit 21 SHINSHINE BIOPHARMA, INC. LIST OF SUBSIDIARIES NOX Pharmaceuticals, Inc. Sunshine Biopharma Canada Inc. Nora Pharma Inc. |
|
| April 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to Commission File Number 001-41282 SUNSHI |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) [X] Form 10-K [] Form 20-F [] Form 11-K [] Form 10-Q [] Form 10-D [] Form N-CEN [] Form N-CSR For Period Ended: December 31, 2022 [] Transition Report on Form 10-K [] Transition Report on Form 20-F [] Transition Report on Form 11-K [] Transition Report on Form 10-Q For the Tra |
|
| March 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2023 SUNSHINE BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commission |
|
| February 28, 2023 |
Exhibit 99.1 For Immediate Release February 28, 2023 SUNSHINE BIOPHARMA SIGNS EXCLUSIVE WORLDWIDE LICENSE WITH UNIVERSITY OF ARIZONA FOR PLpro-BASED COVID-19 TREATMENT Montreal, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announ |
|
| February 28, 2023 |
License Agreement between the Company and the University of Arizona Exhibit 10.1 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed. EXCLUSIVE PATENT LICENSE AGREEMENT Tech Transfer Arizona File(s) [•] and [•] This Exclusive Patent License Agreement (“Agreement”) is effective on the date of the last authorized signature below (“EF |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2023 SUNSHINE BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commiss |
|
| February 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2023 SUNSHINE BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commissi |
|
| February 10, 2023 |
Exhibit 99.1 For Immediate Release February 10, 2023 SUNSHINE BIOPHARMA SIGNS RESEARCH AGREEMENT WITH THE JEWISH GENERAL HOSPITAL TO ADVANCE THE DEVELOPMENT OF Adva-27a ANTICANCER COMPOUND Montreal, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and an |
|
| February 10, 2023 |
Research Agreement between the Company and JGH Exhibit 10.1 RESEARCH AGREEMENT THIS RESEARCH AGREEMENT (“Agreement”) is made as of the last date set forth on the signature page (“Effective Date”), BETWEEN: Sunshine Biopharma Inc., a Nasdaq listed Colorado company (Ticker Symbol: "SBFM") having a place of business at 6500 Trans-Canada Highway, 4th Floor, Pointe-Claire, Quebec, Canada, H9R OA5, herein acting and represented by its duly authorize |
|
| February 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2023 SUNSHINE BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commissi |
|
| December 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K/A Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2022 SUNSHINE BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commis |
|
| December 12, 2022 |
Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Effective October 20, 2022, Sunshine Biopharma, Inc. (“Sunshine” or the “Company”) entered into a Share Purchase Agreement with Nora Pharma Inc. (the “Nora Purchase Agreement”), wherein the Company acquired all of the issued and outstanding shares (the “Shares”) of Nora Pharma Inc. (“Nora”) from Mr. Malek Chamoun. The purcha |
|
| December 9, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2022 SUNSHINE BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commissi |
|
| November 7, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41282 |
|
| November 2, 2022 |
US8677814035 / Sunshine Biopharma Inc / Chamoun Malek - SCHDEULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* SUNSHINE BIOPHARMA INC. (Name of Issuer) COMMON STOCK, par value $0.001 per share (Title of Class of Securities) 867781403 (CUSIP Number) Malek Chamoun 1730 rue Saint Patrick Apt, 601 Montreal, Quebec, Canada H3K 0B2 (Name, Address and Telephone Number of |
|
| October 20, 2022 |
Share Purchase Agreement between Sunshine Biopharma, Inc., Malek Chamoun and Nora Pharma Inc. Exhibit 10.1 SHARE PURCHASE AGREEMENT by and among Sunshine Biopharma Inc. and Malek Chamoun and Nora Pharma Inc. Dated as of October 20, 2022. TABLE OF CONTENTS Article 1 Interpretation 1 1.1 Definitions 1 1.2 Gender and Number 11 1.3 Certain Phrases 11 1.4 Computation of Time Periods 11 1.5 Headings, etc. 11 1.6 Disclosure Schedules, Exhibits and Data Room Disclosure 11 1.7 Currency 12 1.8 Knowl |
|
| October 20, 2022 |
Nora Pharma Inc. Financial Statements June 30, 2022 and 2021 Exhibit 99.2 Nora Pharma Inc. Financial Statements June 30, 2022 and 2021 Financial Statement Report of Independent Registered Public Accounting Firm 2 Balance Sheet 3 Statement of Operations 4 Statement of Changes in Stockholders' Equity (Deficit) 5 Cash Flows 6 Notes to Financial Statements 7 1 Report of Independent Registered Public Accounting Firm To the shareholders and the board of directors |
|
| October 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2022 SUNSHINE BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commissi |
|
| October 20, 2022 |
Employment Agreement between Sunshine Biopharma, Inc., Nora Pharma Inc. and Malek Chamoun Exhibit 10.2 EMPLOYMENT AGREEMENT This employment agreement (the ?Contract?) is entered into as of the 20th day of October, 2022 in the city of Montr?al by and between Nora Pharma Inc., a legal person duly constituted under the laws of the Province of Quebec, (the ?Corporation?), Malek Chamoun, resident and domiciled at 1730 rue Saint-Patrick, apt. 601, Montr?al, Quebec (the ?Employee?)(the Corpor |
|
| October 20, 2022 |
Sunshine Biopharma ANNOUNCES THE ACQUISITION OF NORA PHARMA, ADDING $10.7 MILLION IN REVENUE Exhibit 99.1 For Immediate Release October 20, 2022 Sunshine Biopharma ANNOUNCES THE ACQUISITION OF NORA PHARMA, ADDING $10.7 MILLION IN REVENUE Montreal, Canada ? (GLOBE NEWSWIRE) ? Sunshine Biopharma Inc. (NASDAQ: ?SBFM?), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has completed the acquisition of a |
|
| August 3, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41282 SUNSH |
|
| May 20, 2022 |
14,588,535 Shares of Common Stock Table of Contents Filed pursuant to Rule 424(b)(3) Under the Securities Act of 1933, as amended Registration No. |
|
| May 18, 2022 |
Sunshine Biopharma, Inc. 6500 Trans-Canada Highway 4th Floor Pointe-Claire, Quebec, Canada H9R 0A5 CORRESP 1 filename1.htm Sunshine Biopharma, Inc. 6500 Trans-Canada Highway 4th Floor Pointe-Claire, Quebec, Canada H9R 0A5 May 18, 2022 Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Re: Sunshine Biopharma, Inc. Registration Statement on Form S-3 Filed May 10, 2022 File No. 333- 264830 Ladies and Gentlemen: Pursuant to Rule 461 promulgat |
|
| May 10, 2022 |
As filed with the Securities and Exchange Commission on May 10, 2022 Table of Contents As filed with the Securities and Exchange Commission on May 10, 2022 Registration No. |
|
| May 10, 2022 |
Calculation of Filing Fee Tables Exhibit 107 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered(1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Amount of Registration Fee Common stock, par value $0. |
|
| May 6, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41282 SUNS |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2022 SUNSHINE BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commission |
|
| April 28, 2022 |
EX-10.5 6 sunshineex1005.htm FORM OF PRE-FUNDED WARRANT Exhibit 10.5 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT B |
|
| April 28, 2022 |
Sunshine Biopharma, Inc. Announces Closing of $19.5 Million Private Placement Priced At-the-Market Exhibit 99.2 Sunshine Biopharma, Inc. Announces Closing of $19.5 Million Private Placement Priced At-the-Market MONTREAL, April 28, 2022 (GLOBE NEWSWIRE) - Sunshine Biopharma, Inc. (NASDAQ: ?SBFM? and ?SBFMW?) (the ?Company? or ?Sunshine Biopharma?), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today closed its previously anno |
|
| April 28, 2022 |
Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| April 28, 2022 |
Form of Registration Rights Agreement Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of April 25, 2022, between Sunshine Biopharma, Inc., a Colorado corporation (the ?Company?), and each of the several purchasers signatory hereto (each such purchaser, a ?Purchaser? and, collectively, the ?Purchasers?). This Agreement is made pursuant to the Securities Purcha |
|
| April 28, 2022 |
Form of Securities Purchase Agreement Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of April 25, 2022, between Sunshine Biopharma, Inc., a Colorado corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the terms and conditio |
|
| April 28, 2022 |
Engagement Letter dated April 25, 2022 Exhibit 10.1 AEGIS CAPITAL CORP. April 25, 2022 PERSONAL AND CONFIDENTIAL Dr. Steve Slilaty, Chief Executive Officer Sunshine Biopharma, Inc. 6500 Trans-Canada Highway, 4th Floor Pointe-Claire, Qu?bec, Canada 9R0A5 Re: SBFM Private Placement Dear Dr. Slilaty: The purpose of this engagement letter is to outline our agreement pursuant to which Aegis Capital Corp. (?Aegis?) will act as the placement |
|
| April 28, 2022 |
Sunshine Biopharma, Inc. Announces Pricing of $19.5 Million Private Placement Priced At-the-Market Exhibit 99.1 Sunshine Biopharma, Inc. Announces Pricing of $19.5 Million Private Placement Priced At-the-Market MONTREAL, April 26, 2022 (GLOBE NEWSWIRE) - Sunshine Biopharma, Inc. (NASDAQ: ?SBFM? and ?SBFMW?) (the ?Company? or ?Sunshine Biopharma?), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it entered |
|
| April 8, 2022 |
X0101 EFFECT 33 LIVE 2022-04-08 09:00:00 S-3 0001402328 Sunshine Biopharma, Inc 333-263998 |
|
| April 8, 2022 |
7,207,208 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Under the Securities Act of 1933, as amended Registration No. |
|
| April 8, 2022 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this "Agreement") is entered into on April 8, 2022 (the ?Effective Date?), by and between Sunshine Biopharma, Inc. a Colorado corporation (the "Company"), and Dr. Steve N. Slilaty (the "Executive"). RECITALS WHEREAS, the Executive has been the Company?s Chief Executive Officer since 2009, serving with limited compensation therefore; WHER |
|
| April 8, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2022 SUNSHINE BIOPHARMA, INC. (Exact name of small business issuer as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commissio |
|
| April 7, 2022 |
Sunshine Biopharma, Inc. 6500 Trans-Canada Highway 4th Floor Pointe-Claire, Quebec, Canada H9R 0A5 Sunshine Biopharma, Inc. 6500 Trans-Canada Highway 4th Floor Pointe-Claire, Quebec, Canada H9R 0A5 April 7, 2022 Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Re: Sunshine Biopharma, Inc. Registration Statement on Form S-3 Filed March 30, 2022 File No. 333- 263998 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securiti |
|
| March 30, 2022 |
As filed with the Securities and Exchange Commission on March 30, 2022 As filed with the Securities and Exchange Commission on March 30, 2022 Registration No. |
|
| March 30, 2022 |
Calculation of Filing Fee Tables Exhibit 107 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered(1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Amount of Registration Fee Common stock, par value $0. |
|
| March 24, 2022 |
Exhibit 99.1 Sunshine Biopharma, Inc. 6500 Trans-Canada Highway 4th Floor Pointe-Claire, Quebec, Canada H9R0A5 March 24, 2022 Ladies and Gentlemen: Reference is hereby made to the warrants (?Warrants?) to purchase shares of common stock, dated March 14, 2022, issued by Sunshine Biopharma, Inc. (the ?Company?). By signing below, the undersigned (i) confirms that it is a Holder (as defined in the Wa |
|
| March 24, 2022 |
Financial Statements and Exhibits, Other Events U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2022 SUNSHINE BIOPHARMA, INC. (Exact name of small business issuer as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commissi |
|
| March 21, 2022 |
Description of Registrant’s Securities EX-4.1 2 sunshineex0401.htm DESCRIPTION OF THE REGISTRANT'S SECURITIES Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Sunshine Biopharma, Inc. (the “Company”) has two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended, which are the Company’s common stock, $0.001 par v |
|
| March 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark one) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2021 ? TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to. Commission File Number 001-41282 SUNSH |
|
| March 15, 2022 |
Engagement Letter, dated March 14, 2022, between the Company and Aegis Capital Corp. Exhibit 10.1 AEGIS CAPITAL CORP. March 14, 2022 PERSONAL AND CONFIDENTIAL Dr. Steve Slilaty, Chief Executive Officer Sunshine Biopharma, Inc. 6500 Trans-Canada Highway, 4th Floor Pointe-Claire, Qu?bec, Canada H9R0A5 Re: SBFM Private Placement Dear Dr. Slilaty: The purpose of this engagement letter is to outline our agreement pursuant to which Aegis Capital Corp. (?Aegis?) will act as the placement |
|
| March 15, 2022 |
Registration Rights Agreement, dated March 10, 2022 Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of March 10, 2022, between Sunshine Biopharma, Inc., a Colorado corporation (the ?Company?), and each of the several purchasers signatory hereto (each such purchaser, a ?Purchaser? and, collectively, the ?Purchasers?). This Agreement is made pursuant to the Securities Purcha |
|
| March 15, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2022 SUNSHINE BIOPHARMA, INC. (Exact name of small business issuer as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commissi |
|
| March 15, 2022 |
Sunshine Biopharma, Inc. Announces Closing of $8.0 Million Private Placement Priced At-the-Market Exhibit 99.2 Sunshine Biopharma, Inc. Announces Closing of $8.0 Million Private Placement Priced At-the-Market MONTREAL, Canada, March 14, 2022 (GLOBE NEWSWIRE) - Sunshine Biopharma, Inc. (NASDAQ: ?SBFM? and ?SBFMW?) (the ?Company? or ?Sunshine Biopharma?), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today closed its previous |
|
| March 15, 2022 |
Exhibit 10.5 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| March 15, 2022 |
Sunshine Biopharma, Inc. Announces Pricing of $8.0 Million Private Placement Priced At-the-Market Exhibit 99.1 Sunshine Biopharma, Inc. Announces Pricing of $8.0 Million Private Placement Priced At-the-Market MONTREAL, Canada, March 10, 2022 (GLOBE NEWSWIRE) - Sunshine Biopharma, Inc. (NASDAQ: ?SBFM? and ?SBFMW?) (the ?Company? or ?Sunshine Biopharma?), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it e |
|
| March 15, 2022 |
Securities Purchase Agreement, dated March 10, 2022 Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of March , 2022, between Sunshine Biopharma, Inc., a Colorado corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the terms and conditions |
|
| March 15, 2022 |
Form of Warrant, dated March 14, 2022 Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| February 25, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2022 SUNSHINE BIOPHARMA, INC. (Exact name of small business issuer as specified in its charter) Colorado 000-52898 20-5566275 (State or other jurisdiction of incorporation) (Commi |
|
| February 25, 2022 |
Exhibit 10.1 Research Agreement This Research Agreement (the ?Agreement?) is effective on the date of the last authorized signature below (the "Effective Date"), between Sunshine Biopharma, Inc. (?Sponsor?), with offices located at 6500 Trans-Canada Highway, 4th Floor, Pointe-Claire, Quebec, H9R 0A5, Canada, and the Arizona Board of Regents on behalf of the University of Arizona, an Arizona body c |
|
| February 25, 2022 |
EX-99.1 3 sunshineex9901.htm PRESS RELEASE Exhibit 99.1 For Immediate Release February 25, 2022 SUNSHINE BIOPHARMA EXPANDS ANTI-CORONAVIRUS DRUG DEVELOPMENT PROGRAM BY SIGNING A COLLABORATION AGREEMENT WITH THE UNIVERSITY OF ARIZONA Montreal, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma Inc. (NASDAQ: “SBFM” and SBFMW) (the “Company” or “Sunshine Biopharma”), a pharmaceutical company focused on t |
|
| February 17, 2022 |
Form of Warrant, dated February 17, 2022 EX-4.1 3 sunshineex0401.htm FORM OF WARRANT Exhibit 4.1 COMMON STOCK PURCHASE WARRANT SUNSHINE BIOPHARMA, INC. Warrant Shares: Initial Exercise Date: [*] Issue Date: [*] CUSIP: [*] ISIN: [*] THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [*], or its assigns (the “Holder,” provided that a “Holder” shall include, if the Warrants are held in “street name,” a Pa |
|
| February 17, 2022 |
Table of Contents Filed pursuant to Rule 424(b)(4) Registration No. 333-259394 PROSPECTUS 1,882,353 Units, Each Consisting of One Share of Common Stock and Two Warrants to Purchase Shares of Common Stock Sunshine Biopharma, Inc. is offering 1,882,353 units (the ?Units?), each Unit consisting of one share of our common stock, $0.001 par value, and two warrants (the ?Warrants?), each whole Warrant e |
|
| February 17, 2022 |
Warrant Agent Agreement between the Company and Equiniti , dated February 17, 2022 Exhibit 10.1 WARRANT AGENT AGREEMENT This WARRANT AGENT AGREEMENT (this ?Warrant Agreement?) dated as of February 17, 2022 (the ?Issuance Date?) is between Sunshine Biopharma, Inc., a Colorado corporation (the ?Company?), and Equiniti Trust Company (the ?Warrant Agent?). WHEREAS, pursuant to the terms of that certain Underwriting Agreement (?Underwriting Agreement?), dated February 15, 2022, by an |
|
| February 17, 2022 |
Underwriting Agreement between the Company and Aegis Capital Corp. EX-1.1 2 sunshineex0101.htm UNDERWRITING AGREEMENT BETWEEN SUNSHINE BIOPHARMA, INC. AND AEGIS CAPITAL CORP., DATED FEBRUARY 15, 2022 Exhibit 1.1 1,882,353 UNITS Sunshine Biopharma, Inc. UNDERWRITING AGREEMENT February 15, 2022 Aegis Capital Corp. 810 Seventh Avenue, 18th Floor New York, New York 10019 Ladies and Gentlemen: The undersigned, Sunshine Biopharma, Inc., a corporation formed under the l |
|
| February 17, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2022 SUNSHINE BIOPHARMA, INC. (Exact name of small business issuer as specified in its charter) Colorado 000-52898 20-5566275 (State or other jurisdiction of incorporation) (Commi |
|
| February 17, 2022 |
Exhibit 99.2 Sunshine Biopharma, Inc. Announces Closing of $8 Million Public Offering and Uplisting to the Nasdaq Capital Market MONTREAL, Canada, Feb. 17, 2022 (GLOBE NEWSWIRE) - Sunshine Biopharma, Inc. (NASDAQ: ?SBFM? and ?SBFMW?) (the ?Company? or ?Sunshine Biopharma?), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, announce |
|
| February 17, 2022 |
Exhibit 99.1 Sunshine Biopharma, Inc. Announces Pricing of $8 Million Public Offering and Uplisting to the Nasdaq Capital Market MONTREAL, Canada, Feb. 15, 2022 (GLOBE NEWSWIRE) - Sunshine Biopharma, Inc. (NASDAQ: ?SBFM? and ?SBFMW?) (the "Company" or "Sunshine Biopharma"), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, announce |
|
| February 14, 2022 |
Form of Underwriting Agreement Exhibit 1.1 [*] UNITS Sunshine Biopharma, Inc. UNDERWRITING AGREEMENT [*], 2022 Aegis Capital Corp. 810 Seventh Avenue, 18th Floor New York, New York 10019 Ladies and Gentlemen: The undersigned, Sunshine Biopharma, Inc., a corporation formed under the laws of the State of Colorado (collectively, with its Subsidiaries, the ?Company?), hereby confirms its agreement (this ?Agreement?) with Aegis Capi |
|
| February 14, 2022 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Proposed Maximum Aggregate Offering Price(1) Amount of Registration Fee Common Units (3) $ 11,500,000 (2)(4)(5) $ 1,066. |
|
| February 14, 2022 |
As filed with the Securities and Exchange Commission on February 14, 2022 Table of Contents As filed with the Securities and Exchange Commission on February 14, 2022 Registration No. |
|
| February 14, 2022 |
Exhibit 10.5 COMMON STOCK PURCHASE WARRANT SUNSHINE BIOPHARMA, INC. Warrant Shares: Initial Exercise Date: [*] Issue Date: [*] CUSIP: [*] ISIN: [*] THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, [*], or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or |
|
| February 10, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2022 SUNSHINE BIOPHARMA, INC. (Exact name of small business issuer as specified in its charter) Colorado 000-52898 20-5566275 (State or other jurisdiction of incorporation) (Commis |
|
| February 10, 2022 |
Articles of Amendment to Articles of Incorporation EX-3.7 2 sunshineex0307.htm AMENDMENT TO ARTICLES OF INCORPORATION RE-ESTABLISHING CAPITALIZATION FOLLOWING REVERSE STOCK SPLIT Exhibit 3.7 1 2 ARTICLES OF AMENDMENT Relating to STOCK SPLIT TRANSACTION of SUNSHINE BIOPHARMA, INC Pursuant to CRS 7-106-105 of the Colorado Business Corporation Act I, Dr. Steve N. Slilaty, President and Chief Executive Officer of Sunshine Biopharma, Inc., a corporatio |
|
| February 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGEACT OF 1933 Sunshine Biopharma, Inc. |
|
| February 9, 2022 |
Form of Underwriting Agreement EX-1.1 2 sunshineex0101.htm FORM OF UNDERWRITING AGREEMENT Exhibit 1.1 [*] UNITS Sunshine Biopharma, Inc. UNDERWRITING AGREEMENT [*], 2022 Aegis Capital Corp. 810 Seventh Avenue, 18th Floor New York, New York 10019 Ladies and Gentlemen: The undersigned, Sunshine Biopharma, Inc., a corporation formed under the laws of the State of Colorado (collectively, with its Subsidiaries, the “Company”), hereb |
|
| February 9, 2022 |
CORRESP 1 filename1.htm February 9, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Technology 100 F Street NE Washington, D.C. 20549 Attention: Brian Fetterolf Re: Sunshine Biopharma, Inc. Registration Statement on Form S-1, as amended File No. 333-259394 Initially Filed September 9, 2021 Ladies and Gentlemen: Pursuant to Rule 461 of the General Ru |
|
| February 9, 2022 |
Form of Pre-Funded Warrant for offering Exhibit 10.6 PRE-FUNDED COMMON STOCK PURCHASE WARRANT SUNSHINE BIOPHARMA, INC. Warrant Shares: Initial Exercise Date: [*] Issue Date: [*] CUSIP: [*] ISIN: [*] THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, [*], or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set fo |
|
| February 9, 2022 |
February 9, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| February 9, 2022 |
EX-10.5 6 sunshineex1005.htm FORM OF WARRANT FOR OFFERING Exhibit 10.5 COMMON STOCK PURCHASE WARRANT SUNSHINE BIOPHARMA, INC. Warrant Shares: Initial Exercise Date: [*] Issue Date: [*] CUSIP: [*] ISIN: [*] THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [*], or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise a |
|
| February 9, 2022 |
As filed with the Securities and Exchange Commission on February 9, 2022 As filed with the Securities and Exchange Commission on February 9, 2022 Registration No. |
|
| February 9, 2022 |
Articles of Amendment to Articles of Incorporation Exhibit 3.7 Document must be filed electronically. Paper documents are not accepted. Fees & forms are subject to change. For more information or to print copies of filed documents, visit www.sos.state.co.us. ABOVE SPACE FOR OFFICE USE ONLY Articles of Amendment filed pursuant to ? 7 - 90 - 301, et seq. and ? 7 - 110 - 106 of the Colorado Revised Statutes (C.R.S.) 1. For the entity, its ID number a |
|
| February 9, 2022 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Proposed Maximum Aggregate Offering Price(1) Amount of Registration Fee Common Units (3) $ 11,500,000 (2)(4)(5) $ 1,066. |
|
| February 9, 2022 |
Form of Warrant Agent Agreement Exhibit 10.7 WARRANT AGENT AGREEMENT This WARRANT AGENT AGREEMENT (this ?Warrant Agreement?) dated as of [*], 2022 (the ?Issuance Date?) is between Sunshine Biopharma, Inc., a Colorado corporation (the ?Company?), and Equiniti Trust Company (the ?Warrant Agent?). WHEREAS, pursuant to the terms of that certain Underwriting Agreement (?Underwriting Agreement?), dated [*], 2022, by and among the Comp |
|
| February 8, 2022 |
Exhibit 99.1 Sunshine Biopharma Inc. (OTC Markets: SBFM) ` To the extent that statements in this presentation are not strictly historical, including statements as to revenue projections, future estimates, plans, programs, forecasts, objectives, assumptions, expectations, marketing and sales plans, anticipated revenues, projected market size, beliefs of future performance, business strategy, outloo |
|
| February 8, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2022 SUNSHINE BIOPHARMA, INC. (Exact name of small business issuer as specified in its charter) Colorado 000-52898 20-5566275 (State or other jurisdiction of incorporation) (Commis |
|
| February 3, 2022 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Proposed Maximum Aggregate Offering Price(1) Amount of Registration Fee Common Units (3) $ 11,500,000 (2)(4)(5) $ 1,066. |
|
| February 3, 2022 |
Consent to be named as a director nominee of Dr. Andrew Keller EX-99.2 3 sunshineex9902.htm CONSENT TO BE NAMED AS A DIRECTOR NOMINEE Exhibit 99.2 Consent to be Named as a Director Nominee In connection with the filing by Sunshine Biopharma, Inc. of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 under the Securities A |
|
| February 3, 2022 |
As filed with the Securities and Exchange Commission on February 3, 2022 Table of Contents As filed with the Securities and Exchange Commission on February 3, 2022 Registration No. |
|
| February 3, 2022 |
Consent to be named as a director nominee of David Natan EX-99.1 2 sunshineex9901.htm CONSENT TO BE NAMED AS A DIRECTOR NOMINEE Exhibit 99.1 Consent to be Named as a Director Nominee In connection with the filing by Sunshine Biopharma, Inc. of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 under the Securities A |
|
| January 24, 2022 |
As filed with the Securities and Exchange Commission on January 24, 2022 Table of Contents As filed with the Securities and Exchange Commission on January 24, 2022 Registration No. |
|
| January 24, 2022 |
EX-10.7 2 sunshineex1007.htm SPONSORED RESEARCH AGREEMENT Exhibit 10.7 Identified information has been excluded from the exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. INDUSTRY EXPRESS 2 SPONSORED RESEARCH AGREEMENT This Sponsored Research Agreement (“Agreement”) is between the University of Georgia Research Foundation, Inc., a Georgia no |
|
| January 18, 2022 |
DEF 14C 1 sunshinedef14c.htm DEF 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for use of the Commission only (as permitted by Rule 14c-5(d)(2)) ☒ Definitive Information Statement |
|
| January 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ? Preliminary Information Statement ? Confidential, for use of the Commission only (as permitted by Rule 14c-5(d)(2)) ? Definitive Information Statement SUNSHINE BIOPHARMA, INC. (Name of Re |
|
| December 22, 2021 |
Sunshine Biopharma Announces $1,361,000 in Debt Reduction EX-99.1 2 sunshineex9901.htm PRESS RELEASE Exhibit 99.1 For Immediate Release December 22, 2021 Sunshine Biopharma Announces $1,361,000 in Debt Reduction Montreal, Quebec, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that on December 20, 20 |
|
| December 22, 2021 |
Regulation FD Disclosure, Unregistered Sales of Equity Securities, Financial Statements and Exhibits U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2021 SUNSHINE BIOPHARMA, INC. (Exact name of small business issuer as specified in its charter) Colorado 000-52898 20-5566275 (State or other jurisdiction of incorporation) (Commi |
|
| November 9, 2021 |
Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-52898 SUNSHINE |
|
| November 3, 2021 |
EX-99.1 2 sunshineex9901.htm PRESS RELEASE Exhibit 99.1 For Immediate Release November 3, 2021 SUNSHINE BIOPHARMA EXPANDS BOARD OF DIRECTORS Independent Directors Added as Part of Company’s Application Process to Uplist to Nasdaq Montreal, Quebec, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercializat |
|
| November 3, 2021 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2021 SUNSHINE BIOPHARMA, INC. (Exact name of small business issuer as specified in its charter) Colorado 000-52898 20-5566275 (State or other jurisdiction of incorporation) (Commis |
|
| October 6, 2021 |
DEF 14C 1 sunshinedef14c.htm DEFINITIVE INFORMATION STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for use of the Commission only (as permitted by Rule 14c-5(d)(2)) ☒ Definit |
|
| September 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ? Preliminary Information Statement ? Confidential, for use of the Commission only (as permitted by Rule 14c-5(d)(2)) ? Definitive Information Statement SUNSHINE BIOPHARMA, INC. (Name of Re |
|
| September 9, 2021 |
Exhibit 21 Subsidiaries Sunshine Biopharma Canada Inc. (Canadian) Nox Pharmaceuticals Inc. (Colorado) |
|
| September 9, 2021 |
As filed with the Securities and Exchange Commission on September 8, 2021 Table of Contents As filed with the Securities and Exchange Commission on September 8, 2021 Registration No. |
|
| August 9, 2021 |
Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-52898 SUNSHINE BIOPH |
|
| July 29, 2021 |
SBFM / Sunshine Biopharma, Inc. / Beathard Robert King 3rd - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* SUNSHINE BIOPHARMA, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 867781304 (CUSIP Number) July 20, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| May 11, 2021 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q Quarterly Report Under the Securities Exchange Act of 1934 For Quarter Ended: March 31, 2021 Commission File Number: 000-52898 SUNSHINE BIOPHARMA, INC. (Exact name of small business issuer as specified in its charter) Colorado 20-5566275 (State of other jurisdiction of incorporation) (IRS Employer ID No.) 6500 Trans-Canada Hi |
|
| March 30, 2021 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark one) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2020 ? TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF1934 for the transition period from to. Commission File Number 000-52898 SUNSHINE BIOPHARMA, INC. (Exact n |
|
| November 12, 2020 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q Quarterly Report Under the Securities Exchange Act of 1934 For Quarter Ended: September 30, 2020 Commission File Number: 000-52898 SUNSHINE BIOPHARMA, INC. (Exact name of small business issuer as specified in its charter) Colorado 20-5566275 (State of other jurisdiction of incorporation) (IRS Employer ID No.) 6500 Trans-Canad |
|
| October 19, 2020 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 6, 2020 SUNSHINE BIOPHARMA, INC. (Exact name of small business issuer as specified in its charter) Colorado 000-52898 20-5566275 (State or other jurisdiction of incorporation) (Commiss |
|
| October 19, 2020 |
SUNSHINE BIOPHARMA AND UNIVERSITY OF GEORGIA TEAM UP TO DEVELOP A NEW ANTI-CORONAVIRUS DRUG EX-99.1 2 sbfmex991.htm PRESS RELEASE Exhibit 99.1 For Immediate Release October 19, 2020 SUNSHINE BIOPHARMA AND UNIVERSITY OF GEORGIA TEAM UP TO DEVELOP A NEW ANTI-CORONAVIRUS DRUG Montreal, Canada – (ACCESSWIRE) – Sunshine Biopharma Inc. (OTC Markets: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that |
|
| September 15, 2020 |
SUNSHINE BIOPHARMA SECURES $2,000,000 + FINANCING FOR CORONAVIRUS TREATMENT Exhibit 99.1 For Immediate Release September 15, 2020 SUNSHINE BIOPHARMA SECURES $2,000,000 + FINANCING FOR CORONAVIRUS TREATMENT Montreal, Quebec, Canada - (ACCESSWIRE) - Sunshine Biopharma Inc. (OTC Markets: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has received the first tranche of $250,0 |
|
| September 15, 2020 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2020 SUNSHINE BIOPHARMA, INC. (Exact name of small business issuer as specified in its charter) Colorado 000-52898 20-5566275 (State or other jurisdiction of incorporation) (Comm |
|
| September 15, 2020 |
Financing Agreement with RB Capital Partners, Inc. EX-10.15 2 sbfmex1015.htm FINANCING AGREEMENT WITH RB CAPITAL PARTNERS, INC. Exhibit 10.15 |
|
| August 31, 2020 |
Quarterly Report - AMENDED QUARTERLY REPORT U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q/A Amendment No. 1 Quarterly Report Under the Securities Exchange Act of 1934 For Quarter Ended: June 30, 2020 Commission File Number: 000-52898 SUNSHINE BIOPHARMA, INC. (Exact name of small business issuer as specified in its charter) Colorado 20-5566275 (State of other jurisdiction of incorporation) (IRS Employer ID No.) 650 |
|
| August 19, 2020 |
Quarterly Report - QUARTERLY REPORT U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q Quarterly Report Under the Securities Exchange Act of 1934 For Quarter Ended: June 30, 2020 Commission File Number: 000-52898 SUNSHINE BIOPHARMA, INC. (Exact name of small business issuer as specified in its charter) Colorado 20-5566275 (State of other jurisdiction of incorporation) (IRS Employer ID No.) 6500 Trans-Canada Hig |
